Tempest Therapeutics (TPST – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst ...

In a report released today, George Farmer from Scotiabank maintained a Buy rating on Tempest Therapeutics (TPST – Research Report), with a price target of $13.00. The company’s shares closed yesterday ...

Building upon a successful end-of-Phase 2 meeting, received FDA "Study May Proceed" letter for pivotal Phase 3 trial of amezalpat (TPST-1120) combination therapy to treat first-line HCCAnnounced agree ...

Scotiabank has recently initiated Tempest Therapeutics Inc (TPST) stock to Sector Outperform rating, as announced on March 14, 2024, according to Finviz. Analyst ratings are significant because they ...

On Monday, Tempest Therapeutics Inc (TPST) stock saw a modest uptick, ending the day at $1.1 which represents a slight increase of $0.01 or 0.92% from the prior close of $1.09. The stock opened at ...

The FDA approved a phase 3 trial to assess amezalpat with the current standard of care in unresectable or metastatic ...

This is what could happen next to shares of SoFi Technologies.

At close: November 8 at 4:00 PM EST ...

The Tempest is a new class to the Diablo series and, at least for now, is exclusive to Diablo Immortal. Is this water wizard right for you though? The Tempest is a class that uses the power of the ...